

# Victoria R Nachar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5222781/publications.pdf>

Version: 2024-02-01

13  
papers

68  
citations

1936888

4  
h-index

1588620

8  
g-index

13  
all docs

13  
docs citations

13  
times ranked

114  
citing authors

#	ARTICLE	IF	CITATIONS
1	The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. <i>Leukemia Research</i> , 2018, 70, 91-96.	0.4	20
2	Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 691-698.	0.6	13
3	Chemotherapy Remote Care Monitoring Program: Integration of SMS Text Patient-Reported Outcomes in the Electronic Health Record and Pharmacist Intervention for Chemotherapy-Induced Nausea and Vomiting. <i>JCO Oncology Practice</i> , 2021, 17, e1303-e1310.	1.4	9
4	Implementation and outcomes of a pharmacist-led collaborative drug therapy management program for oncology symptom management. <i>Supportive Care in Cancer</i> , 2021, 29, 6505-6510.	1.0	8
5	Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non-Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases. <i>Annals of Pharmacotherapy</i> , 2021, 55, 697-704.	0.9	6
6	Successful rechallenge of rituximab following severe rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1248-1253.	0.5	4
7	Clinical controversies in the treatment of cancer-associated venous thromboembolism. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 939-953.	0.5	3
8	Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102897.	2.0	2
9	Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-9.	0.6	2
10	PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma. <i>Lancet Oncology</i> , The, 2019, 20, e188.	5.1	1
11	Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 295-308.	0.2	0
12	Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522110724.	0.5	0
13	Incidence and risk factors for bacterial infection in newly diagnosed multiple myeloma patients undergoing treatment with bortezomib, lenalidomide, and dexamethasone (RVD).. <i>Journal of Clinical Oncology</i> , 2022, 40, e20008-e20008.	0.8	0